next 9 days...There's still complete chaos in NASDAQ:GERN , but the quarterly report is approaching, and the market is running out of time to ignore the stock's true valuation. Let's see what happens in the next 9 days. In my view, the chart currently looks like this. A return to the mean looks very promising...
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.2635 EUR
−168.63 M EUR
74.37 M EUR
597.84 M
About Geron Corporation
Sector
Industry
CEO
Dawn Carter Bir
Website
Headquarters
Foster City
Founded
1990
FIGI
BBG01TNXVCD2
Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.
Is $GERN a stock for "Strong Holders"?Or is it just another stock whose value will be wiped out in the next few quarters, and the company will simply lose its listing on the Nasdaq?
Investors are likely to get an answer to this question today, before the market opens, when NASDAQ:GERN reports its quarterly earnings.
The company has
Long GERN @4.43 Oversold in a strong recent uptrend. Will hold each lot until it is both overbought AND profitable. No stops for me. Had a dizzying 40% drawdown back in September '23 and held 14 lots at the bottom of that.
In the end, though, all 14 (and the next 13) turned a profit. The indicator and exit str
GERN - PDUFA Data Release on 16/06/2024Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blo
GERON Corporation Bullish momentum
Title:
GERON Corporation: Bullish Momentum
Overview:
🌟 Hello Traders,
GERON Corporation is currently exhibiting bullish momentum, indicating potential opportunities for traders in the market.
NASDAQ:GERN
Key Points:
- GERON Corporation is experiencing strong bullish momentum, with
Geron's Imetelstat Receives FDA Advisors' BackingGeron Corporation's ( NASDAQ:GERN ) blood disorder drug, Imetelstat, has received a crucial vote of confidence from advisers to the U.S. Food and Drug Administration (FDA). Despite initial concerns raised by the agency's staff regarding data clarity and safety issues, the advisory panel overwhelming
GERON Stock Chart Fibonacci Analysis 022724Trading Idea
1) Find a FIBO slingshot
2) Check FIBO 61.80% level
3) Entry Point > 2.2/61.80%
Chart time frame : B
A) 15 min(1W-3M)
B) 1 hr(3M-6M)
C) 4 hr(6M-1year)
D) 1 day(1-3years)
Stock progress : B
A) Keep rising over 61.80% resistance
B) 61.80% resistance
C) Hit the bottom
D) Hit the top
GERN - long - Catalyst playGeron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a
See all ideas
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Related stocks
Frequently Asked Questions
The current price of 1GERN is 1.2525 EUR — it hasn't changed in the past 24 hours. Watch GERON CORP stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on MIL exchange GERON CORP stocks are traded under the ticker 1GERN.
1GERN stock hasn't changed in a week, the last month showed zero change in price, over the last year there was no change in GERON CORP price.
We've gathered analysts' opinions on GERON CORP future price: according to them, 1GERN price has a max estimate of 6.16 EUR and a min estimate of 1.76 EUR. Watch 1GERN chart and read a more detailed GERON CORP stock forecast: see what analysts think of GERON CORP and suggest that you do with its stocks.
1GERN stock is 0.00% volatile and has beta coefficient of 1.57. Track GERON CORP stock price on the chart and check out the list of the most volatile stocks — is GERON CORP there?
Yes, you can track GERON CORP financials in yearly and quarterly reports right on TradingView.
GERON CORP is going to release the next earnings report on May 7, 2025. Keep track of upcoming events with our Earnings Calendar.
1GERN earnings for the last quarter are −0.039 EUR per share, whereas the estimation was −0.024 EUR resulting in a −62.53% surprise. The estimated earnings for the next quarter are −0.033 EUR per share. See more details about GERON CORP earnings.
GERON CORP revenue for the last quarter amounts to 45.92 M EUR, despite the estimated figure of 59.74 M EUR. In the next quarter, revenue is expected to reach 44.63 M EUR.
1GERN net income for the last quarter is −24.49 M EUR, while the quarter before that showed −23.75 M EUR of net income which accounts for −3.10% change. Track more GERON CORP financial stats to get the full picture.
No, 1GERN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 4, 2025, the company has 229 employees. See our rating of the largest employees — is GERON CORP on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GERON CORP EBITDA is −166.64 M EUR, and current EBITDA margin is −224.06%. See more stats in GERON CORP financial statements.
Like other stocks, 1GERN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GERON CORP stock right from TradingView charts — choose your broker and connect to your account.